Work

Supplemental Figure S1 and Figure S2. from A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure S1 and Figure S2. Figure S1: Pharmacokinetic profiles of PF-03084014 following administration to patients with solid malignancies. Figure S2. Downregulation of Hes4 gene expression following treatment with PF-03084014 in patients with solid malignancies.

DOI: 10.1158/1078-0432.22455395

Authors: Wells A. Messersmith, Geoffrey I. Shapiro, James M. Cleary, Antonio Jimeno, Arvind Dasari, Bo Huang, M. Naveed Shaik, Rossano Cesari, Xianxian Zheng, Jennifer M. Reynolds, Patricia A. English, Karen R. McLachlan, Kenneth A. Kern, Patricia M. LoRusso

Language: English

Topic: Wnt/β-catenin signaling in development and cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361884035

Cites:

Cited by:

Related to: 10